Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 13 other studies
6,975people in the A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure trial, from 2002
4,574of them with heart failure, in this paper
The trial randomly assignedassigned by chance
rosuvastatin 10 mg daily
placebo
No clear effect on deaths from any cause+0%
No clear effect on death or admission to hospital for cardiovascular reasons+1%
randomisedthe abstract, start to end
… group (adjusted hazard ratio [HR] 1.00 [95.5% CI 0.898-1.122], p=0.943). 1305 (57%) patients in the rosuvastatin group and 1283 (56%) in the placebo group died or were admitted to hospital for cardiovascular reasons (adjusted HR 1.01 [99% CI 0.908-1.112], p=0.903).
← favours treatmentfavours comparator →
could be chanceDeath from any causerosuvastatin 10 mg daily vs placebo
HR 1.000.90–1.12
Death or admission to hospital for cardiovascular reasonsrosuvastatin 10 mg daily vs placebo
HR 1.010.91–1.11
StatinsAll-cause mortality
Statins × all-cause mortalityhelps?mixed
unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
1 / 6